| P50 | author | Chin Hur | Q56760983 |
| | Mina Kabiri | Q87496510 |
| P2093 | author name string | Fasiha Kanwal | |
| | Raymond T Chung | |
| | Jagpreet Chhatwal | |
| | Mark S Roberts | |
| | Turgay Ayer | |
| | Xiaojie Wang | |
| | Julie M Donohue | |
| P2860 | cites work | Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement | Q22305313 |
| | Clinical practice. Chronic hepatitis C infection | Q28241445 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States | Q33819963 |
| | The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 |
| | Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients | Q34415766 |
| | Toward a more accurate estimate of the prevalence of hepatitis C in the United States | Q34484872 |
| | Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 |
| | The changing burden of hepatitis C virus infection in the United States: model-based predictions. | Q35168083 |
| | The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection | Q35572125 |
| | Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States | Q35619161 |
| | Hepatocellular carcinoma: recent trends in the United States | Q35929212 |
| | Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 | Q36035889 |
| | Why We Should Be Willing to Pay for Hepatitis C Treatment | Q36075161 |
| | Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 | Q36100389 |
| | Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States | Q37286544 |
| | Cost-effectiveness of novel regimens for the treatment of hepatitis C virus | Q41211125 |
| | Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. | Q42237381 |
| | Liver transplantation in the United States, 1999-2008. | Q43499740 |
| | Trends in organ donation and transplantation in the United States, 1999-2008. | Q44125408 |
| | The impact and evolution of Medicare Part D. | Q44520416 |
| | Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. | Q45226069 |
| | Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness | Q45347587 |
| | Editorial commentary: Hepatitis C virus and the infectious disease physician: a perfect match | Q45358461 |
| | The burden of illness associated with hepatocellular carcinoma in the United States. | Q51124738 |
| | Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1442-1450 | |
| P577 | publication date | 2016-03-25 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals | |
| P478 | volume | 64 | |